11 – 20 of 63
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Potent pro-inflammatory and profibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chaindeficient muscular dystrophy
(
- Contribution to journal › Article
-
Mark
Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells
(
- Contribution to journal › Article
-
Mark
Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD
(
- Contribution to journal › Article
- 2016
-
Mark
Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
(
- Contribution to journal › Article
-
Mark
212th ENMC International Workshop:: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.
(
- Contribution to journal › Article
- 2015
-
Mark
Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice.
(
- Contribution to journal › Article
-
Mark
Deletion of integrin α7 subunit does not aggravate the phenotype of laminin α2 chain-deficient mice.
(
- Contribution to journal › Article
-
Mark
Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.
(
- Contribution to journal › Article
- 2014
-
Mark
Laminin α2 Chain-Deficiency is Associated with microRNA Deregulation in Skeletal Muscle and Plasma.
(
- Contribution to journal › Article
-
Mark
Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.
(
- Contribution to journal › Article